- Home
- App Analytics
- AnticoagEvaluator
- AnticoagEvaluator Vs. Anticoagulation Manager
AnticoagEvaluator vs Anticoagulation Manager Uso e estatísticas
Make well-informed decisions on antithrombotic therapy for your non-valvular AF patients with the updated AnticoagEvaluator.
Use the app to:
• Calculate a patient's renal function and risk of ischemic stroke, thromboembolism, and bleed
• Review ACC/AHA/HRS Guideline-driven therapy guidance for stroke prevention
• Generate individualized risk for antithrombotic therapy options based on individual clinical trials.
• Improve accurate use of DOACs with adjusted dosage based on prescribing information, fine-tuned for renal and other patient characteristics.
This app is based on SPARC Tool, developed by Peter Loewen, ACPR, Pharm.D., FCSHP, which can be viewed at www.sparctool.com
- Apple App Store
- Gratuitos
- Médico
Ranking da Loja
- -
The Anticoagulation Manager is a mobile application developed through the collaborative efforts of the CDC and the Georgia Institute of Technology. Since the determination of the correct type and dose of anticoagulant drugs can be challenging, this application is a resource for clinicians to appropriately order laboratory testing and choose anticoagulant drugs for the various indications. It gives clinicians evidence-based, accessible, and accurate information when prescribing anticoagulants to prevent and/or treat abnormal clotting states.
- Apple App Store
- Gratuitos
- Médico
Ranking da Loja
- -
AnticoagEvaluator versus Anticoagulation Manager comparação de classificação
Compare a tendência de classificação de AnticoagEvaluator nos últimos 28 dias versus Anticoagulation Manager
Classificação
Nenhum dado disponível
Comparação da classificação de AnticoagEvaluator vs. Anticoagulation Manager por país
Compare a tendência de classificação de AnticoagEvaluator nos últimos 28 dias versus Anticoagulation Manager
Nenhum dado para exibir
Faça comparações com qualquer site com o nosso teste grátis
AnticoagEvaluator VS.
Anticoagulation Manager
janeiro 9, 2025